How KCNT1 (Slack) sodium-activated potassium channels are controlled in brain cells
Cellular Regulation of Sodium-activated Potassium Channels
['FUNDING_R01'] · YALE UNIVERSITY · NIH-11235143
This work looks at how a brain channel called KCNT1/Slack that is linked to some childhood epilepsies and autism works, to help guide future treatments for affected children.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | YALE UNIVERSITY (nih funded) |
| Locations | 1 site (NEW HAVEN, UNITED STATES) |
| Trial ID | NIH-11235143 on ClinicalTrials.gov |
What this research studies
Researchers at Yale are studying a brain ion channel called Slack (encoded by KCNT1) that is linked to childhood epilepsies and autism. Using a mouse model carrying a KCNT1 mutation (R455H), they compare two splice versions of the channel (Slack-A and Slack-B) in excitatory versus inhibitory cortical neurons. They will map where each isoform is made with in situ hybridization and immunolocalization, and use antisense oligonucleotides to suppress specific isoforms while measuring sodium and potassium currents and sodium channel protein levels. The team will also examine how altered channel activity changes neuronal firing and mRNA translation that may underlie seizures and developmental problems.
Who could benefit from this research
Good fit: People (especially children) with KCNT1 mutations or families affected by KCNT1-related childhood epilepsy and autism would be the most directly relevant candidates for future therapies from this work.
Not a fit: Patients whose epilepsy or autism is not linked to KCNT1/Slack channel dysfunction are unlikely to receive direct benefit from the approaches tested here in the near term.
Why it matters
Potential benefit: If successful, this work could point to targeted therapies—for example, isoform-specific antisense treatments—that reduce seizures and improve development in people with KCNT1-related epilepsy and autism.
How similar studies have performed: Antisense oligonucleotide approaches have proven effective in other genetic neurological disorders and preclinical data support targeting KCNT1, but human clinical evidence for KCNT1-specific therapies remains limited.
Where this research is happening
NEW HAVEN, UNITED STATES
- YALE UNIVERSITY — NEW HAVEN, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KACZMAREK, LEONARD K — YALE UNIVERSITY
- Study coordinator: KACZMAREK, LEONARD K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Autistic Disorder